H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

August 18, 2026 6:38 AM

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $115.00 price target on Halozyme Therapeutics (NASDAQ: HALO).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found